Neurogastroenterology and Motility最新文献

{"title":"Functional-Structural Correlates in Achalasia: The Relationship of Esophageal Pressurization and Anatomy.","authors":"John E Pandolfino, Eric Goudie, Jacob M Schauer, Domenico A Farina, Leya Chambo, William Ravich, Linda Kelahan, Dustin A Carlson","doi":"10.1111/nmo.70180","DOIUrl":"https://doi.org/10.1111/nmo.70180","url":null,"abstract":"<p><strong>Background and aims: </strong>Achalasia subtypes are classified by high-resolution manometry (HRM) based on esophageal pressurization and contractility patterns, while esophagram-based classifications emphasize esophageal anatomy. We aimed to evaluate the relationship between esophageal pressurization on HRM and esophageal anatomy on esophagram among patients with untreated achalasia.</p><p><strong>Methods: </strong>Adult patients with treatment-naïve achalasia that completed HRM and esophagram were included. HRM achalasia subtypes were determined by the Chicago Classification with pan-esophageal pressurization (PEP) measured among type I and type II achalasia. Anatomy on esophagram was assessed using the Brazilian (esophageal width) and Japanese Esophageal Society (JES; angulation/tortuosity) classifications.</p><p><strong>Results: </strong>222 patients, mean (SD) age 56 (16), 49% female were included. On HRM, 32% were type I, 53% were type II, and 15% were type III achalasia. Esophageal width and JES classification differed by HRM subtype (p-values < 0.001) with type I (HRM) having greatest esophageal width (median (IQR) 5.1(4.0-6.0) cm) and most JES-C 93% (14/15), while type III achalasia had the least (width 2.6 (2.0-3.0) cm) and 0 were JES-C. Among type I and II achalasia, higher esophageal width was significantly correlated with lower median PEP and fewer swallows exceeding PEP thresholds of 10, 15, 20, or 30 mmHg.</p><p><strong>Conclusions: </strong>HRM subtypes and PEP on HRM correlated with esophageal morphology defined on esophagram. However, imperfect concordance between HRM and esophagram classifications suggests complementary value to assess achalasia disease stages related to disease chronicity and esophageal wall mechanics. Future investigations to facilitate combined assessment with HRM and esophagram may enhance achalasia phenotyping and treatment planning.</p>","PeriodicalId":19123,"journal":{"name":"Neurogastroenterology and Motility","volume":" ","pages":"e70180"},"PeriodicalIF":2.9,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145258336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationships Among Gut Microbiota, Plasma Inflammatory Cytokines, and Irritable Bowel Syndrome: A Mediation Mendelian Randomization Study.","authors":"Binbin Tang, Ziwei Mei, Jun Chen, Guang Yu","doi":"10.1111/nmo.70178","DOIUrl":"https://doi.org/10.1111/nmo.70178","url":null,"abstract":"<p><strong>Background: </strong>A relationship may exist between the gut microbiota, inflammatory factors, and irritable bowel syndrome (IBS); however, the precise biological mechanisms linking these components remain uncertain.</p><p><strong>Methods: </strong>In this study, 211 single-nucleotide polymorphisms associated with the gut microbiota were collected from the MiBioGen consortium. Summary data for IBS were sourced from large-scale genome-wide association studies. Two-step Mendelian randomization (MR) was applied to estimate the possible mediating effect of inflammatory cytokines on the causality between the gut microbiota and IBS.</p><p><strong>Results: </strong>MR confirmed the effects of class Melainabacteria, genus Eubacterium hallii group, order Gastranaerophilales, order Rhodospirillales, family Lachnospiraceae, genus Eisenbergiella on IBS prevention. Moreover, MR revealed the role of CD40L receptor levels, interleukin-18 receptor 1 levels, interleukin-1-alpha levels, neurturin levels, neurotrophin-3 levels, stem cell factor levels, signaling lymphocytic activation molecule levels, transforming growth factor-alpha levels, TNF-beta levels, tumor necrosis factor ligand superfamily member 12 levels in IBS. The mediation exploration indicated that the indirect effect of class Melainabacteria (FCS020 group) (id: 11,314) on IBS mediated by Tumor necrosis factor ligand superfamily member 12 levels was OR 1.003 (95% confidence interval 1.000-1.009; mediation proportion = 3.846%).</p><p><strong>Conclusions: </strong>This study supplies genetic insights into the potential causal association between the gut microbiota and IBS. These causal associations and mediating effects are helpful in managing IBS through manipulation of the gut microbiota.</p>","PeriodicalId":19123,"journal":{"name":"Neurogastroenterology and Motility","volume":" ","pages":"e70178"},"PeriodicalIF":2.9,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145258488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Smartphone Application With Health Coaching Facilitates Multi-Symptom Improvement in IBS Patients: A Pilot Feasibility Trial.","authors":"Max Eisele, Munazza Yousuf, Natasha Haskey, Adrijana D'Silva, Yasmin Nasser, Laura Franco, Maitreyi Raman","doi":"10.1111/nmo.70179","DOIUrl":"https://doi.org/10.1111/nmo.70179","url":null,"abstract":"<p><strong>Background: </strong>Irritable bowel syndrome (IBS), a disorder of the gut-brain interaction, is associated with significant symptom burden and impaired psychosocial functioning. Evidence-based behavioral therapies are effective, but often underutilized due to accessibility barriers. Mobile health is an emerging field with the potential to bridge the gap between the needs of individuals with IBS and the limitations of the healthcare system. This study evaluated the feasibility and effectiveness of the LyfeMD app plus health coaching (HC) in improving IBS symptom severity and psychosocial wellbeing.</p><p><strong>Methods: </strong>This 12-week interventional pilot study evaluated the effectiveness of a mobile application combined with HC in adults diagnosed with IBS. Participants were assessed at baseline, 6 weeks, and 12 weeks using validated surveys to assess symptom severity, psychosocial wellbeing, diet, physical activity, and sleep. A Fitbit was also used to track physical activity and sleep.</p><p><strong>Results: </strong>Thirty-nine participants completed the 12-week intervention. IBS symptom severity improved significantly (p < 0.001) over the 12-week period, with 63.2% of the participants having a clinically meaningful improvement in their symptoms. In addition to symptom severity, participants improved in all measured psychosocial domains and their subjective sleep quality at 12 weeks.</p><p><strong>Conclusion: </strong>In summary, the LyfeMD platform, in combination with HC, shows potential in improving IBS symptom severity, psychosocial well-being, and sleep quality in individuals diagnosed with IBS. These findings highlight the potential of mobile health as a complement to traditional medical care. Further research, including randomized controlled trials with extended follow-up, is needed to confirm findings and the sustainability of these outcomes.</p>","PeriodicalId":19123,"journal":{"name":"Neurogastroenterology and Motility","volume":" ","pages":"e70179"},"PeriodicalIF":2.9,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145239238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to \"Avoiding the Use of Long-Term Parenteral Support in Patients Without Intestinal Failure: A Position Paper From the European Society of Clinical Nutrition & Metabolism, the European Society of Neurogastroenterology and Motility and the Rome Foundation for Disorders of Gut-Brain Interaction\".","authors":"","doi":"10.1111/nmo.70143","DOIUrl":"https://doi.org/10.1111/nmo.70143","url":null,"abstract":"","PeriodicalId":19123,"journal":{"name":"Neurogastroenterology and Motility","volume":" ","pages":"e70143"},"PeriodicalIF":2.9,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145213306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practical Validation of the COuGH RefluX Score: A Multicenter Study in Patients From Hispano-America.","authors":"Luis G Alcala-Gonzalez, Alberto Ezquerra-Duran, Francisco Alejandro Félix Téllez, Anna Calm, Fermin Estremera, Claudia Barber, Ariadna Aguilar, Raúl Alberto Jiménez Castillo, Elizabeth Barba, Ingrid Marin, Irene Areste, Daniel Cisternas, Enrique Coss-Adame, José María Remes Troche, Jordi Serra","doi":"10.1111/nmo.70072","DOIUrl":"10.1111/nmo.70072","url":null,"abstract":"<p><strong>Background: </strong>Laryngopharyngeal reflux symptoms (LPS) are often attributed to gastroesophageal reflux disease (GERD), yet objective testing confirms GERD in only a small subset of patients. The COuGH RefluX score, previously validated in North American and Taiwanese populations, offers a non-invasive method to stratify GERD likelihood in patients with LPS. This study aimed to evaluate its performance in a real-world Hispano-American cohort.</p><p><strong>Methods: </strong>We performed a multicenter, retrospective cohort study in 459 adult patients from seven Neurogastroenterology units in Spain and Latin America, referred for LPS between 2018 and 2024. All patients underwent endoscopy, high-resolution esophageal manometry, and 24-h pH or Ph-impedance monitoring. Two versions of the COuGH RefluX score-original (including endoscopy and manometry data) and practical (including only endoscopy data)-were calculated. GERD status was defined per Lyon 2.0 criteria.</p><p><strong>Key results: </strong>Proven GERD was identified in 164 patients (36%). The original COuGH RefluX score showed an AUC of 0.706, with 89% sensitivity and 89% specificity. The practical version showed an AUC of 0.684, maintaining the same sensitivity and specificity (both 89%). Compared to the original COuGH RefluX score, the practical version misclassified 54 patients due to undetected hiatal hernia on endoscopy alone; among these, 15 patients initially classified as indeterminate were downgraded to low likelihood-4 with proven GERD and 11 with unproven GERD. A subset of 197 (43%) patients reported at least three cough episodes during reflux monitoring. Among those with strong symptom association (n = 18), 67% had a high COuGH RefluX score, suggestive of a high GERD likelihood.</p><p><strong>Conclusions: </strong>The COuGH RefluX score effectively stratifies GERD probability in patients with LPS. It may also identify patients with significant symptom-reflux associations, guiding targeted testing and therapy. This pragmatic tool could improve resource allocation by reducing unnecessary invasive testing in low-risk patients.</p>","PeriodicalId":19123,"journal":{"name":"Neurogastroenterology and Motility","volume":" ","pages":"e70072"},"PeriodicalIF":2.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144020291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Mediterranean Diet vs. Low-FODMAP Diet in Patients With Nonconstipated Irritable Bowel Syndrome: A Pilot Randomized Controlled Trial.","authors":"Prashant Singh, Gregory Dean, Sofia Iram, Westley Peng, Samuel W Chey, Samara Rifkin, Christine Lothen-Kline, Jane Muir, Allen A Lee, Shanti Eswaran, William D Chey","doi":"10.1111/nmo.70060","DOIUrl":"10.1111/nmo.70060","url":null,"abstract":"<p><strong>Introduction: </strong>Mediterranean diet (MD) has been proposed as a dietary therapy for irritable bowel syndrome (IBS) but its efficacy remains unclear. We compared the efficacy of MD to a diet low in fermentable oligo-, di-, monosaccharides, and polyols (LFD).</p><p><strong>Methods: </strong>In this pilot-feasibility, randomized controlled trial (RCT), adult patients with diarrhea-predominant IBS (IBS-D) or mixed bowel pattern (IBS-M) were randomized to MD versus LFD for 4 weeks. Meals were provided for both groups (ModifyHealth, GA). Daily variables included abdominal pain intensity (API) and bloating, while IBS symptom severity score (IBS-SSS) and IBS adequate relief (IBS-AR) were scored weekly. The primary endpoint was the proportion of patients with ≥ 30% decrease in API for ≥ 2/4 weeks.</p><p><strong>Results: </strong>Of 26 randomized patients, 20 finished the study (10 per group). Seventy-three percent of the MD group met the primary endpoint compared to 81.8% of the LFD group (p = 1.0). Although not statistically significant, a numerically higher proportion of the LFD group reported adequate relief and met the responder endpoint for IBS-SSS (50-point reduction) compared to the MD group (54.6% vs. 27.3% for IBS-AR and 81.8% vs. 45.5% for IBS-SSS, p = 0.39 and 0.18, respectively). The LFD group also had a significantly greater reduction in IBS-SSS score over the 4-week treatment period compared to the MD group (-105.5 vs. -60, p = 0.02).</p><p><strong>Conclusion: </strong>MD provides symptom relief in IBS-D and IBS-M; however, the magnitude of relief was higher with the LFD. Larger diet comparison studies in real-world settings are needed before MD can be routinely recommended to IBS patients.</p><p><strong>Trial registration: </strong>Clinicaltrials.gov: NCT05807919.</p>","PeriodicalId":19123,"journal":{"name":"Neurogastroenterology and Motility","volume":" ","pages":"e70060"},"PeriodicalIF":2.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12435798/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Amomum tsao-ko Attenuates Hyperglycemia and Cognitive Impairment via Regulating Gut Microbiota, SCFAs, and CREB/BDNF/TrkB Signaling Pathway in T2DM Mice.","authors":"Caixia Wang, Huilin Ren, Zhen Wang, Ruixue Min, Xiaoli Chen, Yanli Ma, Xiaofeng Zhang","doi":"10.1111/nmo.70065","DOIUrl":"10.1111/nmo.70065","url":null,"abstract":"<p><strong>Background: </strong>As a medicine-food fruit, Amomum tsao-ko has been reported to be beneficial for the management of diabetes. However, its effects and mechanisms in the cognitive impairment caused by diabetes remain unclear. This study aimed to investigate the influences of A. tsao-ko on cognitive impairment in type 2 diabetes mellitus (T2DM) mice and associated mechanisms.</p><p><strong>Methods: </strong>A. tsao-ko was characterized using UHPLC-Q-Orbitrap-MS/MS. T2DM mice induced by a high-fat diet combined with streptozotocin were treated with ethanol extract of A. tsao-ko (EEAT) for 8 weeks. The cognitive function was evaluated by the Morris water maze (MWM) test, open field test (OFT), and novel object recognition test (NORT). Hippocampus and colon tissues were used for histopathology, biochemical assays, or protein expression analysis. Additionally, fecal samples were subjected to 16S rRNA gene sequencing and short-chain fatty acids (SCFAs) detection.</p><p><strong>Key results: </strong>The findings demonstrated that EEAT significantly reversed glucose metabolism disorders and cognitive deficits in T2DM mice. It promoted the protein expression of the CREB/BDNF/TrkB pathway and reduced hippocampal inflammatory responses, thereby improving neuronal damage. It inhibited the loss of colonic tight junction proteins, decreased the levels of inflammatory factors in the colon, and also reshaped the gut microbiota and increased SCFAs. Notably, Spearman's correlation analysis indicated that the Lachnospiraceae NK4A136 group, Ruminococcaceae UCG-014, Lactobacillus, Blautia, and Lachnoclostridium were obviously correlated (positive or negative) with glucose homeostasis indexes, behavioral indexes, tissue inflammatory factors, and SCFAs.</p><p><strong>Conclusions: </strong>The regulating effects of Amomum tsao-ko on gut microbiota, SCFAs, and the CREB/BDNF/TrkB pathway may be potential mechanisms for alleviating cognitive impairment in diabetes, which provides a potential option to treat diabetic cognitive impairment.</p>","PeriodicalId":19123,"journal":{"name":"Neurogastroenterology and Motility","volume":" ","pages":"e70065"},"PeriodicalIF":2.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144020747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of Digital Rectal Exam Compared With High-Resolution Anorectal Manometry in the Diagnosis of Dyssynergic Defecation in Pediatrics.","authors":"Carolina Alexandra Zambrano Pérez, Erick Manuel Toro-Monjaraz, Samuel Nurko, Oscar Pérez-González, José Cadena-León, Karen Ignorosa-Arellano, Roberto Cervantes-Bustamante, Jaime Ramirez-Mayans, Ericka Montijo Barrios, Flora Zárate-Mondragón","doi":"10.1111/nmo.70061","DOIUrl":"10.1111/nmo.70061","url":null,"abstract":"<p><strong>Background: </strong>Currently, high-resolution anorectal manometry (HRAM) is the only way to confirm the diagnosis of defecatory dyssynergia; however, it has limitations in pediatric patients. Digital rectal examination (DRE) may suggest the presence of defecatory dyssynergia based on clinical findings, but it is not a definitive diagnostic method. Its role in pediatric patients remains unexplored. The objective of this study was to determine the usefulness of DRE as a diagnostic test for dyssynergic defecation in pediatric patients compared with HRAM.</p><p><strong>Methods: </strong>Patients aged 5-18 years who were referred for HRAM in a third-level hospital in Mexico City between March 2022 and September 2022 were included. Altered propulsion or impaired push effort was considered a suggestive diagnosis of dyssynergia by DRE. The results were compared with those obtained using HRAM.</p><p><strong>Results: </strong>Forty-two patients were included, of whom 50% were male, with a median age of 10.68 years (standard deviation [SD] 3.23). Dyssynergia was diagnosed by DRE in 21 patients (50%) and by HRAM in 21 patients (50%). A sensitivity of 66% and a specificity of 66% were calculated for the alteration of rectal propulsion in DRE as suggestive of dyssynergia when compared to HRAM. A positive predictive value of 66% and a negative predictive value of 66% were calculated.</p><p><strong>Conclusions and inferences: </strong>The sensitivity and specificity of DRE for the diagnosis of dyssynergic defecation were lower than those reported for adults (75% and 85%, respectively). In some cases, DRE would be useful, especially in low-resource scenarios where HRAM is not available, and we recommend DRE prior to HRAM as a complementary approach to dyssynergic defecation.</p>","PeriodicalId":19123,"journal":{"name":"Neurogastroenterology and Motility","volume":" ","pages":"e70061"},"PeriodicalIF":2.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144032317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survey of Current Practices and Experiences of Clinicians Treating Irritable Bowel Syndrome (IBS) With Cognitive Behavioral Therapy and/or Gut-Directed Hypnosis.","authors":"Sarah Kinsinger, Olafur Palsson","doi":"10.1111/nmo.70058","DOIUrl":"10.1111/nmo.70058","url":null,"abstract":"<p><strong>Introduction: </strong>Cognitive behavioral therapy (CBT) and gut-directed hypnosis (GDH) are the two most widely used brain-gut behavior therapies (BGBT) for irritable bowel syndrome (IBS), but nearly all that is known about their clinical effects comes from formal trials rather than clinical practice. We aimed to collect data from BGBT practitioners on their use and perception of these treatments, including positive and negative effects in their most recently treated patients.</p><p><strong>Methods: </strong>Rome Foundation Psychogastroenterology section listserv members and other clinicians known to regularly treat IBS with CBT or GDH (166 total) were invited via email to participate in a de-identified Internet survey. The survey included questions about their demographics, nature of their clinical practice, ratings of different outcomes for their last two patients completing each treatment, adverse effects of treatment, factors perceived as important for successful treatment outcomes, and use of virtual therapy.</p><p><strong>Results: </strong>The survey was completed by 58 therapists. Most (82.8%) reported using both CBT and GDH in their practice. Their ratings of outcomes for their last two patients completing each treatment (ratings for a total of 162 patients included in analysis) showed moderate or large positive treatment effects for a substantial majority of patients in four of the five outcome domains for both therapies, including improvements in bowel symptoms, emotional symptoms, life functioning, and ability to cope with/self-manage IBS symptoms. Adverse effects (rated as mild, moderate, or severe) associated with therapy were reported for six CBT patients (5.2%, all mild) and two GDH patients (2.7%; 1 mild, 1 moderate). The mean number of sessions was 9.6 for CBT (range 2-76) and 7.6 for GDH (range 3-23). Treatment was entirely or partly virtual (via video) for 79.5% of CBT and 76.9% of GDH patients. Most therapists using virtual therapy rated it as at least as effective as in-person therapy for both CBT (86.8%) and GDH (78.4%). Only one therapist reported having ever encountered serious adverse effects of GDH, and two therapists for CBT, in their clinical careers.</p><p><strong>Conclusion: </strong>This survey provides a unique real-world snapshot of current practice and experiences among therapists treating IBS with CBT and/or GDH. The results indicate that both therapies provide multiple moderate or large therapeutic benefits for the majority of treated IBS patients, with a very low burden of associated adverse effects. Virtual delivery is now the norm for these interventions and is generally found to be as effective as in-person treatment by the therapists.</p>","PeriodicalId":19123,"journal":{"name":"Neurogastroenterology and Motility","volume":" ","pages":"e70058"},"PeriodicalIF":2.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12435796/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144033882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intestinal Dysmotility and Associated Disorders in Intestinal Muscle of Methylglyoxal-Treated Mice.","authors":"Yuki Yamakawa, Taiki Mihara, Masatoshi Hori","doi":"10.1111/nmo.70068","DOIUrl":"10.1111/nmo.70068","url":null,"abstract":"<p><strong>Background: </strong>Peritoneal dialysis (PD) is a renal replacement therapy approach to treat end-stage renal failure. However, complications such as gastrointestinal dysmotility occur in patients undergoing PD, and the mechanisms underlying these complications have not been elucidated. We hypothesized that inflammation and dysfunction of the interstitial cells of Cajal (ICC) contribute to the PD-induced gastrointestinal dysmotility.</p><p><strong>Methods: </strong>Mice were intraperitoneally administered a dialysate containing methylglyoxal (40 mM) every other day for 2 weeks to mimic the gastrointestinal complications in patients undergoing long-term PD. The gastrointestinal transit capacity was evaluated using fluorescent dyes that were forcibly administered orally. To evaluate the inflammation and function of the ICC in the intestinal muscles, we performed real-time polymerase chain reaction and immunohistochemical staining and measured spontaneous contractions ex vivo.</p><p><strong>Key results: </strong>The intestinal transit capacity was significantly reduced in the methylglyoxal-treated group compared to that in the control group. In the inflammatory evaluation, the number of neutrophils and macrophages in the intestinal muscles significantly increased in the methylglyoxal-treated group compared to the control group. Moreover, the mRNA expression levels of Tnf, Il1b, and Il6 were upregulated in the intestinal muscle from the methylglyoxal-treated group. The mRNA expression of Kit, an interstitial cell of Cajal marker, was significantly decreased in the methylglyoxal-treated group. In addition, the frequency of spontaneous contractions, an index of ICC function, was decreased in the methylglyoxal-treated group.</p><p><strong>Conclusions and inference: </strong>Our data suggest that the PD-induced gastrointestinal dysmotility might be due to inflammation and dysfunction of the ICC in intestinal muscles.</p>","PeriodicalId":19123,"journal":{"name":"Neurogastroenterology and Motility","volume":" ","pages":"e70068"},"PeriodicalIF":2.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12435800/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144036663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}